Drug intelligence / Profile preview

amlodipine + candesartan cilexetil + hydrochlorothiazide

Development stage
Unknown
Lead developer
Cardiotech Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Aracure Plus is a fixed-dose combination antihypertensive medication containing three active ingredients: candesartan cilexetil (an angiotensin II receptor blocker), amlodipine besylate (a dihydropyridine calcium channel blocker), and hydrochlorothiazide (a thiazide diuretic). Developed and marketed by Cardiotech Pharmaceutical, it is indicated for the treatment of essential hypertension, particularly in patients whose blood pressure is not adequately controlled by monotherapy or dual-combination therapies. By combining three distinct mechanisms of action—vasodilation via calcium channel blockade, inhibition of angiotensin II-mediated vasoconstriction, and promotion of diuresis and natriuresis—Aracure Plus provides synergistic blood pressure reduction and helps reduce the risk of cardiovascular events.

Brand names
Aracure Plus
Other names
amlodipine + candesartan + hydrochlorothiazideamlodipine + candesartan cilexetil + hydrochlorothiazidecandesartan + amlodipine + hydrochlorothiazidecandesartan cilexetil + amlodipine + hydrochlorothiazidecandesartan cilexetil + amlodipine besylate + hydrochlorothiazidecandesartan cilexetil, amlodipine, and hydrochlorothiazidecandesartan, amlodipine, and hydrochlorothiazide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)AGTR2 (AT2)CA (Carbonic anhydrase)LTCC (Voltage-gated calcium channel (L-type))SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on amlodipine + candesartan cilexetil + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + candesartan cilexetil + hydrochlorothiazide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call